Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18257723 | 0.86 | ALDH1A1 (0.64) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA | |
| SCHEMBL41372 | 0.84 | ALDH1A1 (0.82) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA | |
| SCHEMBL1582969 | 0.80 | ALDH1A1 (0.91) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA | |
| SCHEMBL1820762 | 0.80 | ALDH1A1 (1.00) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA | |
| SCHEMBL8970657 | 0.78 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA | |
| SCHEMBL8971393 | 0.78 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA | |
| SCHEMBL8971703 | 0.78 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA | |
| SCHEMBL4001371 | 0.78 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA | |
| SCHEMBL2870934 | 0.78 | PSIP1 (0.54) | ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL8971186 | 0.78 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4736892-A2 | METHODS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | Cerus Corporation (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3852817-B1 | METHODS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | CERUS CORP (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | CERUS CORP (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250216379-A1 | SYSTEMS AND METHODS FOR TESTING AND SCREENING USING COMPOUND BOUND SUBSTRATES | CERUS CORP (US) | 2025-07-03 | — | — | US | disclosed |
| US-12282015-B2 | Systems and methods for testing and screening using compound bound substrates | CERUS CORPORATION (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2024221045-A1 | IMMUNOGENIC COMPOSITION | GRIFFITH UNIVERSITY (AU) | 2024-10-31 | — | — | WO | disclosed |
| US-20230408490-A1 | SYSTEMS AND METHODS FOR TESTING AND SCREENING USING COMPOUND BOUND SUBSTRATES | CERUS CORPORATION | 2023-12-21 | — | — | US | disclosed |
| US-20230263833-A1 | COMPOSITIONS AND METHODS FOR PREPARATION OF RED BLOOD CELLS | CERUS CORPORATION | 2023-08-24 | — | — | US | disclosed |
| US-20220031917-A1 | METHODS AND KITS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | MIDCAP FINANCIAL TRUST | 2022-02-03 | — | — | US | disclosed |
| CN-113271975-A | Method and kit for preparing pathogen inactivated whole blood | 塞鲁斯公司 | 2021-08-17 | — | — | CN | disclosed |
| EP-1085880-A2 | USE OF ALKYLATING COMPOUNDS FOR INHIBITING PROLIFERATION OF ARTERIAL SMOOTH MUSCLE CELLS | Cerus Corporation (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1045704-A1 | METHODS FOR QUENCHING PATHOGEN INACTIVATORS IN BIOLOGICAL MATERIALS | Cerus Corporation (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1021414-A1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6093725-A | A BINDER FOR DEACTIVATING PATHOGENS IN A BLOOD SAMPLE TO BIND NUCLEIC ACID BY COVALENT LINKAGE | CERUS CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1005531-A2 | METHOD OF TREATING LEUKOCYTES, LEUKOCYTE COMPOSITIONS AND METHODS OF USE THEREOF | Cerus Corporation (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999063981-A2 | USE OF ALKYLATING COMPOUNDS FOR INHIBITING PROLIFERATION OF ARTERIAL SMOOTH MUSCLE CELLS | CERUS CORPORATION (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999034839-A1 | METHODS FOR QUENCHING PATHOGEN INACTIVATORS IN BIOLOGICAL MATERIALS | CERUS CORPORATION (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999003976-A2 | METHOD OF TREATING LEUKOCYTES, LEUKOCYTE COMPOSITIONS AND METHODS OF USE THEREOF | CERUS CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998030545-A9 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | — | 1998-12-30 | — | — | WO | disclosed |
| WO-1998030545-A1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034277-A1 | SYSTEMS AND METHODS FOR PATHOGEN INACTIVATION OF BLOOD PRODUCTS | PRF1, CFD, F5 | ALDH1A1 3817/4885CYP2C19 966/4885CYP3A4 1147/4885 |
| US-20220031917-A1 | METHODS AND KITS FOR PREPARING PATHOGEN-INACTIVATED WHOLE BLOOD | HBG1, THPO, HBG2 | ALDH1A1 3407/4885CYP2C19 2375/4885CYP3A4 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.